InvestorsHub Logo

runncoach

12/17/22 7:14 AM

#21065 RE: HANUMAN #21062

I think sava has a decent shot. If I was them I might be concerned after seeing us show a positive placebo response even after 6 months considering their initial trial had no placebo however.

I don't think any of these alternative plays have a better than 50/50 shot. As Perry said, he likes to see newer drugs that attempt to aid the body's own defense mechanisms instead of just targeting plaques. Of course we know of supplements and healthy lifestyle choices that can do this as well so its believable that a drug could potentially do this better. As we've now seen with a few recent alternate plays, they're no miracles. Some relief perhaps but not hugely above current SOC. Maybe SAVA will be the one. Clearly the leader in a very failed space. Jmho

Investor2014

12/17/22 11:08 AM

#21071 RE: HANUMAN #21062

I think SAVA has as much of a chance as Synaptogenix had.